Balance sheet as at December 31
(in CHF)
|
|
|
Notes |
|
2020 |
|
2019 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
25 022 |
|
135 028 |
|
Other current receivables |
|
|
|
5 639 574 |
|
6 291 277 |
|
|
|
|
|
5 664 596 |
|
6 426 305 |
|
Non-current assets |
|
|
|
|
|
|
|
Investments |
|
|
|
1 177 069 500 |
|
1 177 069 500 |
|
|
|
|
|
1 177 069 500 |
|
1 177 069 500 |
|
Total assets |
|
|
|
1 182 734 096 |
|
1 183 495 805 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Other current liabilities |
|
2.1 |
|
381 190 |
|
404 609 |
|
Accrued expenses |
|
|
|
440 145 |
|
326 699 |
|
|
|
|
|
821 335 |
|
731 308 |
|
Total liabilities |
|
|
|
821 335 |
|
731 308 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
2.2 |
|
11 080 000 |
|
11 080 000 |
|
Legal capital reserves |
|
|
|
|
|
|
|
– Paid-in capital reserve 1) |
|
|
|
20 579 224 |
|
20 579 224 |
|
Legal profit reserves |
|
|
|
|
|
|
|
– General legal reserve |
|
|
|
4 500 000 |
|
4 500 000 |
|
– Reserve for treasury shares 2) |
|
|
|
8 241 195 |
|
– |
|
Other reserves |
|
|
|
218 586 561 |
|
226 827 756 |
|
Retained earnings |
|
5/6 |
|
918 925 781 |
|
919 777 517 |
|
|
|
|
|
1 181 912 761 |
|
1 182 764 497 |
|
Total liabilities and shareholders' equity |
|
|
|
1 182 734 096 |
|
1 183 495 805 |
1 Of which CHF 20 441 000 not confirmed by the Swiss Tax Authorities due to present regulation
2 For treasury shares held by subsidiaries
The financial statements were approved by the Board of Directors of BB Biotech AG on February 16, 2021.